Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Ueda Y, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Okamura J, Tamai H, Nakamura S, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tada F, Ohama H, Koshiyama Y, Kanayama Y, Noritake H, Komatsu S, Fukumoto T, Matsuura T, Kim SK, Enomoto H, Matsui K, Kaibori M, Hiasa Y, Kudo M, Kumada T, Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group.

Open source

DOI: 10.1111/liv.70803
Published: 2026-08-01
Container: Liver Int
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/liv.70803,
  title = {Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.},
  author = {Tanaka K and  Tsuji K and  Hiraoka A and  Tada T and  Hirooka M and  Kariyama K and  Tani J and  Atsukawa M and  Takaguchi K and  Itobayashi E and  Nishimura T and  Ishikawa T and  Tajiri K and  Tanaka H and  Toyoda H and  Ogawa C and  Hatanaka T and  Kakizaki S and  Kawata K and  Naganuma A and  Kosaka H and  Matono T and  Ueda Y and  Kuroda H and  Yata Y and  Nishikawa H and  Imai M and  Aoki T and  Ochi H and  Okamura J and  Tamai H and  Nakamura S and  Nakamura Y and  Yoshida O and  Nouso K and  Morishita A and  Itokawa N and  Okubo T and  Arai T and  Tsutsui A and  Nagano T and  Tada F and  Ohama H and  Koshiyama Y and  Kanayama Y and  Noritake H and  Komatsu S and  Fukumoto T and  Matsuura T and  Kim SK and  Enomoto H and  Matsui K and  Kaibori M and  Hiasa Y and  Kudo M and  Kumada T and  Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group.},
  year = {2026},
  journal = {Liver Int},
  doi = {10.1111/liv.70803},
  url = {https://doi.org/10.1111/liv.70803}
}

RIS

TY  - JOUR
TI  - Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
AU  - Tanaka K
AU  -  Tsuji K
AU  -  Hiraoka A
AU  -  Tada T
AU  -  Hirooka M
AU  -  Kariyama K
AU  -  Tani J
AU  -  Atsukawa M
AU  -  Takaguchi K
AU  -  Itobayashi E
AU  -  Nishimura T
AU  -  Ishikawa T
AU  -  Tajiri K
AU  -  Tanaka H
AU  -  Toyoda H
AU  -  Ogawa C
AU  -  Hatanaka T
AU  -  Kakizaki S
AU  -  Kawata K
AU  -  Naganuma A
AU  -  Kosaka H
AU  -  Matono T
AU  -  Ueda Y
AU  -  Kuroda H
AU  -  Yata Y
AU  -  Nishikawa H
AU  -  Imai M
AU  -  Aoki T
AU  -  Ochi H
AU  -  Okamura J
AU  -  Tamai H
AU  -  Nakamura S
AU  -  Nakamura Y
AU  -  Yoshida O
AU  -  Nouso K
AU  -  Morishita A
AU  -  Itokawa N
AU  -  Okubo T
AU  -  Arai T
AU  -  Tsutsui A
AU  -  Nagano T
AU  -  Tada F
AU  -  Ohama H
AU  -  Koshiyama Y
AU  -  Kanayama Y
AU  -  Noritake H
AU  -  Komatsu S
AU  -  Fukumoto T
AU  -  Matsuura T
AU  -  Kim SK
AU  -  Enomoto H
AU  -  Matsui K
AU  -  Kaibori M
AU  -  Hiasa Y
AU  -  Kudo M
AU  -  Kumada T
AU  -  Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group.
PY  - 2026
JO  - Liver Int
DO  - 10.1111/liv.70803
UR  - https://doi.org/10.1111/liv.70803
ER  -

APA

K, T., K, T., A, H., T, T., M, H., K, K., J, T., M, A., K, T., E, I., T, N., T, I., K, T., H, T., H, T., C, O., T, H., S, K., K, K., A, N., H, K., T, M., Y, U., H, K., Y, Y., H, N., M, I., T, A., H, O., J, O., H, T., S, N., Y, N., O, Y., K, N., A, M., N, I., T, O., T, A., A, T., T, N., F, T., H, O., Y, K., Y, K., H, N., S, K., T, F., T, M., SK, K., H, E., K, M., M, K., Y, H., M, K., T, K., & Group., R. P. E. F. H. (. S. G. A. H. C. E. F. 4. C. I. J. (. 4. (2026). Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.. Liver Int. https://doi.org/10.1111/liv.70803

Source records

europe-pmc · retrieved 2026-09-25T11:00:35.330Z